Ablynx Stock

Stocks

15/10/18	AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	RE
27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
17/04/18	Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
22/03/18	Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
29/01/18	Ablynx : Chipmakers, Sanofi deal dominate European share trading	RE
29/01/18	Ablynx : Novo Nordisk remains on hunt for biopharma deals	RE
22/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
22/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

19/11/20	Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	AQ
19/06/18	Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
25/05/18	Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	GL

19/06/18	SANOFI : a finalisé l'acquisition d'Ablynx
14/05/18	Les marchés européens marquent une pause, scrutent la politique italienne
14/05/18	Sanofi : A suivre aujourd'hui
14/05/18	SANOFI : détient 95,60% des actions d'ABLYNX
27/04/18	Sanofi : Les taux de change freinent les résultats, T2 terne en vue

Manager	Title	Age	Since
Geert Deschamps CEO	Chief Executive Officer	-	07/03/2025

Director	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	01/04/2019
Pieter Oldenziel BRD	Director/Board Member	-	01/01/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABLYNX	-.--%	+0.09%	-	-	0
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
ABIVAX	-0.08%	-3.01%	+1,271.69%	+649.69%	11.76B
Average	+0.17%	+0.04%	+223.08%	+179.48%	22.91B
Weighted average by Cap.	+0.24%	+0.36%	+171.43%	+187.42%